Rethinking multiple sclerosis therapy beyond clinical phenotypes

Résumé fourni par la source

Sormani et al. argue that multiple sclerosis should be viewed as a biological continuum rather than distinct clinical forms. Evidence from recent trials suggests that therapies targeting shared biological mechanisms can slow disability progression across the disease spectrum, supporting a shift away from traditional classifications.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.